Plasma BNP in patients on maintenance haemodialysis: a guide to management?

Area of Science:

• Nephrology
• Cardiology
• Biomarkers

Background:

• Long-term haemodialysis patients face a high burden of cardiovascular disease, accounting for most deaths.
• Current management strategies are insufficient to mitigate this excessive cardiovascular risk.

Purpose of the Study:

• To explore the potential of cardiac natriuretic peptides, specifically B-type natriuretic peptide (BNP), as objective guides for managing haemodialysis patients.
• To investigate if targeting plasma BNP levels can reduce cardiovascular stress and disease incidence.

Main Methods:

• Literature review on cardiac natriuretic peptide levels in haemodialysis patients.
• Analysis of the relationship between natriuretic peptide levels, cardiac load, and haemodialysis.
• Examination of the predictive value of natriuretic peptides for cardiovascular outcomes.

Main Results:

• Plasma natriuretic peptide levels are elevated in haemodialysis patients, reflecting cardiac preload, afterload, and pathology.
• Natriuretic peptide levels correlate with cardiac load, particularly during haemodialysis.
• Evidence indicates natriuretic peptide levels predict cardiovascular outcomes in this population.

Conclusions:

• Cardiac natriuretic peptides, especially BNP, show promise as biomarkers for guiding hydration and pharmacotherapy in haemodialysis.
• Hypothesized that lowering plasma BNP to normal ranges via optimized haemodialysis and targeted pharmacotherapy could reduce cardiovascular burden and disease incidence.
• A clinical trial design to test this hypothesis is proposed.